Advances in the management of acute myeloid Leukemia in older adult patients

Oncology Nursing Forum

Volumn 37, Issue 3, 2010, Pages

  Rogers, Barbara B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; CYTARABINE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CLASSIFICATION; HUMAN; METHODOLOGY; MIDDLE AGED; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; PATIENT EDUCATION; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL SUPPORT; STEM CELL TRANSPLANTATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CYTARABINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; SOCIAL SUPPORT; STEM CELL TRANSPLANTATION;

EID: 77955288133     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/10.ONF.E168-E179     Document Type: Article

References (54)

1. American Cancer Society. (2009). Cancer facts and figures 2009. Retrieved from http://www.cancer.org/downloads/STT/500809web.pdf
2. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Will-man, C.L., Godwin, J.E., Petersdorf, S.H. (2006). Age and acute myeloid leukemia. Blood, 107, 3481-3485. doi: 10.1182/blood-2005-09-3724
3. Aribi, A., Ravandi, F., & Giles, F. (2006). Novel agents in acute myeloid leukemia. Cancer Journal, 12, 77-91.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., & Sultan, C. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. The French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620-625.
5. Buchner, T., Berdel, W.E., Wormann, B., Schoch, C., Haferlach, T., Schnittger, S., Hiddemann, W. (2005). Treatment of older patients with AML. Critical Reviews in Oncology/Hematology, 56, 247-259. doi: 10.1016/j.critrevonc. 2004.09.010 (Pubitemid 41568580)
6. Burnett, A.K., & Mohite, U. (2006). Treatment of older patients with acute myeloid leukemia - New agents. Seminars in Hematology, 43, 96-106. doi: 10.1053/j.seminhematol.2006.01.003
7. Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Cancer and Leukemia Group B (CALGB 8461). (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325-4336. (Pubitemid 35429670)
8. Cashen, A., Schiller, G., Larsen, J., Cullen, M.T., DiPersio, J.F. (2006). Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). ASH Annual Meeting Abstracts, 108, 1984.
9. de la Serna, J., Montesinos, P., Vellenga, E., Rayón, C., Parody, R., León, A,. Sanz, M.A. (2008). Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 3395-3402. doi: 10.1182/blood-2007-07-100669
10. Deschler, B., & Lubbert, M. (2006). Acute myeloid leukemia: Epidemiology and etiology. Cancer, 107, 2099-2107. doi: 10.1002/cncr.22233 (Pubitemid 44665642)
11. Döhner, K., & Döhner, H. (2008). Molecular characterization of acute myeloid leukemia. Haematologica, 93, 976-982. doi: 10.3324/haematol.13345 (Pubitemid 351957013)
12. Epstein, J.B., & Schubert, M.M. (1999). Oral mucositis in myelosup-pressive cancer therapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 88, 273-276. doi: 10.1016/S10792104(99)70026-0
13. Estey, E. (2006). General approach to and perspectives on clinical research in older patients with newly diagnosed acute myeloid leukemia. Seminars in Hematology, 43, 89-95. doi: 10.1053/j.seminhematol.2006.01.002
14. Estey, E. (2007). Acute myeloid leukemia and myelodysplastic syndromes in older patients. Journal of Clinical Oncology, 25, 1908-1915. doi: 10.1200/JCO.2006.10.2731 (Pubitemid 46854425)
15. Estey, E., & Döhner, H. (2006). Acute myeloid leukemia. Lancet, 368, 1894-1907. doi: 10.1016/S0140-6736(06)69780-8 (Pubitemid 44794525)
16. Farag, S.S., Archer, K.J., Mrozek, K., Ruppert, A.S., Carroll, A.J., Cardiman, J.W., Bloomfield, C.D. (2006). Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood, 108, 63-73. doi: 10.1182/blood-2005-11- 4354 (Pubitemid 43996625)
17. Geller, R.B. (1996). Use of cytokines in the treatment of acute myelocytic leukemia: A critical review. Journal of Clinical Oncology, 14, 1371-1382. (Pubitemid 26105548)
18. Giles, F.J., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garci-Manero, G., Waddelow, T.A., Estey, E.H. (2001). Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413. doi: 10.1002/1097-0142(20010715)92:2<406::AIDCNCR1336>3.0.CO;2-U (Pubitemid 32664448)
19. Greiner, J., Döhner, H., & Schmitt, M. (2006). Cancer vaccines for patients with acute myeloid leukemia - Definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica, 91, 1653-1661. (Pubitemid 46039635)
20. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J.,. Medical Research Council Adult Leukemia Working Party. (2001). The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia: Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320. doi: 10.1182/blood.V98.5.1312
21. Harris, D.J., Eilers, J., Harriman, A., Cashavelly, B.J., & Maxwell, C. (2008). Putting Evidence Into Practice: Evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology Nursing, 12, 141-152. doi: 10.1188/08.CJON.141-152
22. Harris, D.J., & Knobf, M.T. (2004). Assessing and managing chemotherapy-induced mucositis pain. Clinical Journal of Oncology Nursing, 8, 622-627. doi: 10.1188/04.CJON.622-628
23. Harris, N., Jaffe, E., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J.,. Bloomfield, C.D. (1999). World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Journal of Clinical Oncology, 17, 3835-3849. Retrieved from http://jco.ascopubs.org/cgi/content/full/17/12/3835
24. Higa, G.M., Gockerman, J.P., Hunt, A.L., Jones, M.R., & Horne, B.J., (1991). The use of prophylactic eye drops during high-dose cytosine arabinoside. Cancer, 68, 1691-1693.
25. Jabbour, E.J., Estey, E., & Kantarjian, H.M. (2006). Adult acute myeloid leukemia. Mayo Clinic Proceedings, 81, 247-260. doi: 10.4065/81.2.247 (Pubitemid 43205780)
26. Jackson, G.H., & Taylor, P.R.A. (2002). Acute myeloid leukaemia: Optimising treatment in elderly patients. Drugs and Aging, 19, 571-581. doi: 10.2165/00002512-200219080-00003
27. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E.,. Estey, E. (2006). Results of intensive chemotherapy in 998 patients age 65 or older with acute myeloid leukemia or high-risk myelo-dysplastic syndrome: Predictive prognostic models for outcome. Cancer, 106, 1090-1098. doi: 10.1002/cncr.21723
28. King, M., & Rowe, J. (2007). Recent developments in acute myelogenous leukemia therapy. Oncologist, 12(Suppl. 2), 14-21.
29. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A.,. Linch, D.C. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
30. Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Willman, C.L. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood, 94, 1086-1099. (Pubitemid 29361842)
31. Lowenberg, B., Boogaerts, M., Daenen, S., Verhoef, G.E., Hagenbeek, A., Vellenga, E.,. van Putten, W.L. (1997). Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during and after induction therapy of acute myeloid leukemia. Journal of Clinical Oncology, 15, 3496-3506. (Pubitemid 27527723)
32. Lowenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E., Vellegna, E.,. Zittoun, R. (1997). Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group. Blood, 90, 2952-2961.
33. Lubbert, M., Rüter, B., Claus, R., Schmid, M., Germing U., & Eimermacher, H. (2007). Continued low-dose decitabine is an active first line treatment in all cytogenetic subgroups of older AML patients: Results of the FR00331 multicenter phase II study [Abstract]. Blood, 110, 300.
34. Markovic, A., MacKenzie, K.L., & Lock, R.B. (2005). FLT-3: A new focus in the understanding of acute leukemia. International Journal of Biochemistry and Cell Biology, 37, 1168-1172. doi: 10.1016/j.biocel.2004.12.005 (Pubitemid 40381193)
35. Mayer, R., Davis, R., Schiffer, C., Berg, D.T., Powell, B.L., Schulman, P.,. Frei, E., III. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903. doi: 10.1056/NEJM199410063311402 (Pubitemid 24299870)
36. Melchert, M. (2006). Managing acute myeloid leukemia in the elderly. Oncology, 20, 1674-1682.
37. Mrózek, K., Marcucci, G., Paschka, P., Whitman, S.P., & Bloomfield, C.D. (2007). Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood, 109, 431-448. doi: 10.1182/blood-2006-06-001149 (Pubitemid 46105936)
38. National Cancer Institute. (2008a). Search for clinical trials. Retrieved from http://www.cancer.gov/clinicaltrials/search
39. National Cancer Institute. (2008b). Surveillance Epidemiology and End Results. Cancer statistics: AML. Retrieved from http://www.seer.cancer.gov/ statfacts/html/amyl.html?statfacts-page=amyl.html&x=18&y=18.
40. National Comprehensive Cancer Network. (2009). NCCN Practice Guidelines in Oncology™: Acute myeloid leukemia [v.2.2010]. Retrieved from http://www.nccn.org/professionals/physician-gls/PDF/aml.pdf
41. Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T.,. Saito, Y. (1994). A double-blind controlled study of granulocyte- stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood, 83, 2086-2092. Retrieved from http://bloodjournal.hematologylibrary.org/cgi/reprint/83/8/2086 (Pubitemid 24112719)
42. Pinto, A., Zagonel, V., & Ferrara, F. (2001). Acute myeloid leukemia in the elderly: Biology and therapeutic strategies. Critical Reviews in Oncology/Hematology, 39, 275-287. doi: 10.1016/S1040-8428(00)00122-0 (Pubitemid 32750296)
43. Redaelli, A., Stephens, J.M., Brandt, S., Botteman, M.F., & Pashos, C.L. (2004). Short-and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treatment Reviews, 30, 103-117. doi: 10.1016/S0305-7372(03)00142-7 (Pubitemid 38240090)
44. Sanz, M., Tallman, M., & Lo-Coco, F. (2005). Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia. Oncologist, 10, 806-814. doi: 10.1634/theoncologist.10-10-806 (Pubitemid 43152698)
45. Sekeres, M.A. (2006). Non-transplant therapy for older adults with acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 4, 51-56. (Pubitemid 44265380)
46. Sekeres, M.A., & Stone, R.M. (2002). The challenge of acute myeloid leukemia in older patients. Current Opinion in Oncology, 14, 24-30. doi: 10.1097/00001622-200201000-00005 (Pubitemid 34072959)
47. Sekeres, M.A., Stone, R.M., Zahrieh, D., Morrison, V., DeAngelo, D.J., Galinsky, I., & Lee, S.J. (2004). Decision-making and quality of life in older adults with AML or advanced MDS. Leukemia, 18, 809-816. doi: 10.1038/sj.leu.2403289 (Pubitemid 38500200)
48. Simpson, J.K., & Rosenzweig, M.Q. (2002). Treatment considerations for the elderly person with cancer. AACN Clinical Issues, 13, 43-60. doi: 10.1097/00044067-200202000-00006
49. Stock, W. (2006). Controversies in treatment of AML: Case-based discussion. Hematology, 185-191.
50. Stone, R.M. (2002). The difficult problem of acute myeloid leukemia in the older adult. CA: A Cancer Journal for Clinicians, 52, 363-371. doi: 10.3322/canjclin.52.6.363 (Pubitemid 35446607)
51. Sudan, N., Rossetti, J.M., Shadduck, R.K., Latsco, J., Lech, J.A., Kaplan, R.B.,. Lister, J. (2006). Treatment of acute myelogenous leukemia with azacitidine. Cancer, 107, 1839-1843. doi: 10.1002/cncr.22204 (Pubitemid 44582953)
52. Yancik, R. (1997). Cancer burden in the aged: An epidemiologic and demographic overview. Cancer, 80, 1271-1283.
53. Zitella, L., Gobel, B., & O'Leary, C. (2009). Prevention of infection. In L. Eaton & J. Tipton (Eds.), Putting Evidence Into Practice: Improving oncology patient outcomes (pp. 267-283). Pittsburgh, PA: Oncology Nursing Society.
54. Zittoun, R., Suciu, S., Mandelli, F., de White, T., Thaler, J., Stryckmans, P.,. Willemze, R. (1996). Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology, 14, 2150-2159. (Pubitemid 26230119)